Cargando…

SAT-309 Integrated Analysis of Pituitary Adenoma Using Novel Approach of Non-Target Proteomics Along with RNA-Sequencing Analyses

Objective: To clarify the relationship between proteomic expression and clinical feature of pituitary adenoma. Methods: We have previously developed non-target proteomics analysis, which enables to detect and quantify approximately 7,000 to 9,000 kinds of protein weave, in parallel with RNA-seq anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yue, Nagano, Hidekazu, Horiguchi, Kentaro, Hashimoto, Naoko, Nakayama, Akitoshi, Higuchi, Seiichiro, Yamagata, Kazuyuki, Yokoyama, Masataka, Iwadate, Yasuo, Tanaka, Tomoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207513/
http://dx.doi.org/10.1210/jendso/bvaa046.1681
_version_ 1783530622741905408
author Gao, Yue
Nagano, Hidekazu
Horiguchi, Kentaro
Hashimoto, Naoko
Nakayama, Akitoshi
Higuchi, Seiichiro
Yamagata, Kazuyuki
Yokoyama, Masataka
Iwadate, Yasuo
Tanaka, Tomoaki
author_facet Gao, Yue
Nagano, Hidekazu
Horiguchi, Kentaro
Hashimoto, Naoko
Nakayama, Akitoshi
Higuchi, Seiichiro
Yamagata, Kazuyuki
Yokoyama, Masataka
Iwadate, Yasuo
Tanaka, Tomoaki
author_sort Gao, Yue
collection PubMed
description Objective: To clarify the relationship between proteomic expression and clinical feature of pituitary adenoma. Methods: We have previously developed non-target proteomics analysis, which enables to detect and quantify approximately 7,000 to 9,000 kinds of protein weave, in parallel with RNA-seq analysis, and then subjected to 14 cases of pituitary adenoma surgically removed at Chiba University Hospital. Bioinformatic evaluation including DEGs, heatmap and PCA analyses was performed to reveal underlying their molecular pathogenesis. Results: We successfully identified 789 differentially expressed proteins and 593 DEGs in non-target proteomics and RNA-seq, respectively. Intriguingly, PCA analysis demonstrated that tumors were clearly divided into 3 groups based on protein expression profile; functional pituitary adenomas consisting of two subtypes depending on Pit1 and T-pit linage, and non-functional tumors consisting of two distinct subtypes, with properties close to functional tumors and unique characteristics of hard tumor difficult to remove by endoscopic surgery. To address the underlying molecular biological functions in each group clustering analysis and heat-map were performed and we found that 3 groups were separated clearly with their own both gene and protein expression profile. Indeed, for instance, GO term of plasma membrane part was significantly enriched in hard tumor group, pathways of GH receptor signaling, GH hormone synthesis as in GH-positive group. Conclusions: We herein demonstrate that pituitary adenoma can be uniquely separated into certain categories through our novel non-target proteomics with coupling to RNA-seq, particularly providing novel group of hard tumor characteristics with enriched expression of both protein and mRNA in plasma membrane part. Thus our method would be beneficial and useful to elucidate underlying molecular pathogenesis for pituitary tumors, while further analysis is required.
format Online
Article
Text
id pubmed-7207513
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72075132020-05-13 SAT-309 Integrated Analysis of Pituitary Adenoma Using Novel Approach of Non-Target Proteomics Along with RNA-Sequencing Analyses Gao, Yue Nagano, Hidekazu Horiguchi, Kentaro Hashimoto, Naoko Nakayama, Akitoshi Higuchi, Seiichiro Yamagata, Kazuyuki Yokoyama, Masataka Iwadate, Yasuo Tanaka, Tomoaki J Endocr Soc Neuroendocrinology and Pituitary Objective: To clarify the relationship between proteomic expression and clinical feature of pituitary adenoma. Methods: We have previously developed non-target proteomics analysis, which enables to detect and quantify approximately 7,000 to 9,000 kinds of protein weave, in parallel with RNA-seq analysis, and then subjected to 14 cases of pituitary adenoma surgically removed at Chiba University Hospital. Bioinformatic evaluation including DEGs, heatmap and PCA analyses was performed to reveal underlying their molecular pathogenesis. Results: We successfully identified 789 differentially expressed proteins and 593 DEGs in non-target proteomics and RNA-seq, respectively. Intriguingly, PCA analysis demonstrated that tumors were clearly divided into 3 groups based on protein expression profile; functional pituitary adenomas consisting of two subtypes depending on Pit1 and T-pit linage, and non-functional tumors consisting of two distinct subtypes, with properties close to functional tumors and unique characteristics of hard tumor difficult to remove by endoscopic surgery. To address the underlying molecular biological functions in each group clustering analysis and heat-map were performed and we found that 3 groups were separated clearly with their own both gene and protein expression profile. Indeed, for instance, GO term of plasma membrane part was significantly enriched in hard tumor group, pathways of GH receptor signaling, GH hormone synthesis as in GH-positive group. Conclusions: We herein demonstrate that pituitary adenoma can be uniquely separated into certain categories through our novel non-target proteomics with coupling to RNA-seq, particularly providing novel group of hard tumor characteristics with enriched expression of both protein and mRNA in plasma membrane part. Thus our method would be beneficial and useful to elucidate underlying molecular pathogenesis for pituitary tumors, while further analysis is required. Oxford University Press 2020-05-08 /pmc/articles/PMC7207513/ http://dx.doi.org/10.1210/jendso/bvaa046.1681 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Gao, Yue
Nagano, Hidekazu
Horiguchi, Kentaro
Hashimoto, Naoko
Nakayama, Akitoshi
Higuchi, Seiichiro
Yamagata, Kazuyuki
Yokoyama, Masataka
Iwadate, Yasuo
Tanaka, Tomoaki
SAT-309 Integrated Analysis of Pituitary Adenoma Using Novel Approach of Non-Target Proteomics Along with RNA-Sequencing Analyses
title SAT-309 Integrated Analysis of Pituitary Adenoma Using Novel Approach of Non-Target Proteomics Along with RNA-Sequencing Analyses
title_full SAT-309 Integrated Analysis of Pituitary Adenoma Using Novel Approach of Non-Target Proteomics Along with RNA-Sequencing Analyses
title_fullStr SAT-309 Integrated Analysis of Pituitary Adenoma Using Novel Approach of Non-Target Proteomics Along with RNA-Sequencing Analyses
title_full_unstemmed SAT-309 Integrated Analysis of Pituitary Adenoma Using Novel Approach of Non-Target Proteomics Along with RNA-Sequencing Analyses
title_short SAT-309 Integrated Analysis of Pituitary Adenoma Using Novel Approach of Non-Target Proteomics Along with RNA-Sequencing Analyses
title_sort sat-309 integrated analysis of pituitary adenoma using novel approach of non-target proteomics along with rna-sequencing analyses
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207513/
http://dx.doi.org/10.1210/jendso/bvaa046.1681
work_keys_str_mv AT gaoyue sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT naganohidekazu sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT horiguchikentaro sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT hashimotonaoko sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT nakayamaakitoshi sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT higuchiseiichiro sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT yamagatakazuyuki sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT yokoyamamasataka sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT iwadateyasuo sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses
AT tanakatomoaki sat309integratedanalysisofpituitaryadenomausingnovelapproachofnontargetproteomicsalongwithrnasequencinganalyses